New study maps quality of life burden in rare heart disease

Researchers have documented how transthyretin amyloid cardiomyopathy affects patients' everyday functioning and wellbeing. The findings could help pharmaceutical companies and health systems better measure treatment success and design patient support programs for this serious but treatable condition.

Originaltitel: Health-related quality of life among transthyretin amyloid cardiomyopathy patients